Formycon continues to secure launches in global markets for its ranibizumab biosimilar FYB201 as the German firm introduces the Lucentis rival in Canada and Switzerland, where it will be marketed as Ranopto and Ranivisio, respectively.
Ranopto was approved by Health Canada late last year, but at the time, the commercial launch was expected to begin in Q1 2024
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?